Last reviewed · How we verify
A-101 Topical Solution
At a glance
| Generic name | A-101 Topical Solution |
|---|---|
| Sponsor | Aclaris Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of A-101 for the Treatment of Seborrheic Keratosis (PHASE2)
- Safety Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- A Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- Study of A-101 Topical Solution for the Treatment of Common Warts (PHASE3)
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra (PHASE2)
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (PHASE4)
- A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis (PHASE2)
- A Phase2 of A-101 Topical Solution in Subjects With Common Warts (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |